Wenbin Jiang - Feb 21, 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
President and CEO, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Stock symbol
CTKB
Transactions as of
Feb 21, 2023
Transactions value $
-$28,884
Form type
4
Date filed
2/23/2023, 05:43 PM
Previous filing
Feb 8, 2023
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise +6.76K +0.09% 7.73M Feb 21, 2023 Direct F1
transaction CTKB Common Stock Tax liability -$28.9K -2.63K -0.03% $10.97 7.72M Feb 21, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Restricted Stock Units Options Exercise $0 -6.76K -7.89% $0.00 78.9K Feb 21, 2023 Common Stock 6.76K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.